We simplify
market access for
medical devices
Our proven experts guide you through medical device
CE certification. You gain hands-on support in
regulatory affairs and quality management, ensuring
regulatory compliance. Plus, as a Swiss Authorised
Representative, we facilitate your access to the
medical device market in Switzerland.
One partner for your medical device compliance

Obtain CE mark with proven experts
Decomplix becomes your professional compliance partner. We guide you to your CE mark and ensure your compliant quality management. You get expert advice on how to overcome key regulatory hurdles on the way to getting your product to market.
More about our CE mark services

CE-certified medical device software
Transform your algorithm into a CE-certified medical device software in less than a year. Decomplix, with its partner platform Evidencio, can offer a fast, proven, de-risked solution.
More about our medical device software service

Swiss Authorised Representative
As your Swiss Authorised Representative (CH-REP), we ensure your market access in Switzerland. Our high level of compliance and regulatory knowledge was confirmed with a Swissmedic inspection with no non-conformities in April 2022.
More about our CH-REP service

Compliance for Swiss medical device importers
We offer consulting, training and ready-to-use templates for procedures, checklists and other tools for the compliant import of medical devices into Switzerland. Our proven experts tailor the processes together with you to your needs for fixed price.
More about our importers service

Swissmedic: Inspection of importers
In 2025, Swissmedic will inspect Swiss importers of medical devices for compliance with the MedDO and IvDO. Our experts will prepare you efficiently for the inspection so that you do not risk any interruption to your business.
More about our inspection readiness check
100+ medical device and in-vitro diagnostic companies of all shapes and sizes trust Decomplix — from startups to corporates, from Switzerland to all around the globe.
Read more about us
Regulatory Affairs News
23.10.2025.
European Commission
The last amendment to the official list of Harmonised Standards (i.e. Implementing Decision (EU) 2025/2078 of 17 October 2025) only introduced standards relative to surgical clothing and drapes, medical face masks, and low temperature steam and formaldehyde sterilizers. It is however important to be aware that a new Consolidated List of HS under the EU MDR is now available.
Swissmedic
The information sheet for the cosmetic sector – Parenterals without an intended medical purpose is newly published, which provides guidance on some borderline topics. Although it is intended as a pharmaceutical/cosmetic borderline guideline, it covers injectables that can also be Annex XVI products and clarifies how such products qualify as regards enforcement and provides an overview and guidance for professionals, particularly those working in the cosmetic sector.
03.10.2025.
Swissmedic
The swissdamed User Guide UDI Devices Module V.2 has been published, featuring the addition of Chapter 8, “Discard UDIs”:
- Registered UDI-DIs may be discarded if they contain incorrect data that cannot be corrected via an update.
- A reason must be provided when discarding the UDIs
- The discarded UDIs will be listed in the “My UDIs” section
EU Commission
The EU Commission’s consultation process on the draft guidance and form for reporting serious incidents for high-risk AI systems under the AI Act is running until November 7th. The final guidance and form shall become applicable on August 2nd, 2026.
For medical devices and IVDs, this reporting would only apply to infringement of fundamental rights that significantly interfere with Charter-protected rights on a large scale, as all other serious incidents relative to AI-enabled medical device software would be routed through EU MDR/IVDR Vigilance.
26.09.2025.
MedTech Europe
MedTech Europe has published an internal guidance to its members on their participation in the European Commission’s public Call for Evidence concerning the targeted revision of the EU rules on medical devices and IVD. Key areas for feedback are as follows:
- Reducing administrative burden
- Enhancing predictability and cost-efficiency of NB processes
- Making conformity assessment proportional (fast-track reviews for low-risk/well established technologies, accelerated/holistic pathways for special devices, etc.)
- Enabling further digitalisation
- Streamlining procedures, including governance
- Benefiting from international cooperation (MDSAP, MRA with CH, etc.)
- Better alignment with other relevant legislation (e.g., AIA, EHDS, GDPR, REACH, PLD, etc.)
An open letter to the EC Commissioner on the targeted review of medical device legislation was published, outlining different proposals of actions needed to provide short-term relief while laying the foundation for a fully functioning regulatory system:
- The legislative reform should cover both EU MDR and IVDR.
- NBs should be overseen by a single & accountable governance structure.
- Urgent (short-term) relief measures are needed:
- An implementing act for NB setting maximum assessment timelines, defining the scope of notified changes, removing duplication of vigilance review, enabling early dialogues with the MFR and mitigating the re-certification.
- Regulatory pathways for orphan & paediatric devices and breakthrough innovations.
- Postponement of re-certification until the end of the transitional periods (2028) to allow NBs to focus on new certifications.
Latest from our blog

You will receive regular updates around regulation of medical devices.
